QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)
QQQ   354.84 (-0.02%)
AAPL   179.21 (-0.21%)
MSFT   333.68 (-0.67%)
META   271.12 (-0.10%)
GOOGL   127.31 (+1.03%)
AMZN   126.61 (+1.05%)
TSLA   221.31 (+1.70%)
NVDA   386.54 (-1.32%)
NIO   7.87 (+2.61%)
BABA   86.69 (+2.71%)
AMD   124.23 (+5.34%)
T   15.66 (+1.75%)
F   12.93 (+2.70%)
MU   67.54 (-0.34%)
CGC   0.74 (-5.13%)
GE   105.46 (+1.31%)
DIS   92.16 (+1.27%)
AMC   4.64 (+0.22%)
PFE   38.37 (-0.72%)
PYPL   65.02 (+0.79%)
NFLX   399.29 (-1.05%)

3 Dividend Contenders to Buy Now for Long-Term Gains Later

Key Points

  • Dividend contenders are companies that have increased their dividend for between 10 and 24 years. 
  • Investors should look for a combination of a low price and an attractive annual payout per share to maximize their compound growth. 
  • Brookfield Asset Management gives investors an all-of-the-above approach to the energy sector. 
  • Pfizer is moving beyond the pandemic which makes it a strong candidate for long-term growth.
  • Corning is an under-the-radar dividend contender that may benefif from the trend to onshore. 
  • 5 stocks we like better than Brookfield Asset Management

Dividend contenders stocks

Dividend contenders are a group of companies that have increased the dividend they pay to shareholders for at least 10 years up to 24 years. There are currently over 360 such companies. This article highlights three of these stocks that you can buy now to get long-term gains later.  

Dividend stocks are a good fit in any portfolio. If your primary goal is income, dividend stocks can provide a steady stream of cash. You can use the cash to supplement your income, or you can reinvest it, which allows you to benefit from compounding.  And even if you’re a growth-oriented investor, a few quality dividend stocks provide diversification and can smooth out the volatility of your more aggressive stock picks. 

If you’re looking to buy dividend stocks for the long haul, it’s good to find a stock that doesn’t cost you too much per share but pays an attractive annual dividend per share. This allows you to take the greatest advantage of compounding the growth you get by reinvesting these dividends quarter after quarter for many years.  

A stock screener can be helpful in this regard. For these three stocks, I was looking at stocks that were currently selling for less than $70 per share with a dividend yield of higher than 3% (S&P 500 average is approximately 2.5% as of this writing). 

It’s Like Owning an ETF With One Stock 

If you’re a believer in the all-of-the-above approach to our nation’s energy future, Brookfield Asset Management Ltd. NYSE: BAM is a stock to consider. The company has over $750 billion in assets under management. The company’s renewable energy portfolio covers hydroelectric, wind, and solar assets. It also has an infrastructure business that aids the operation and development of utilities, transport, midstream, data and sustainable resource assets. 


The company has a price-to-earnings (P/E) ratio of around 18x. That's a little expensive, but analysts expect earnings growth of over 17% in the next five years, so it may not be overvalued for long. And that type of growth should easily help cover the company’s dividend which it has increased for 12 consecutive years. It currently has a yield of 4.05% with an annual payout of $1.28 per share.  

An Investment in the Future of Medicine 

Pfizer, Inc. NYSE: PFE has been a polarizing stock for many investors. And the performance of PFE stock in the last 12 months is not awe-inspiring. It’s down nearly 25%. However, the company’s recent acquisition of Seagen, Inc. NASDAQ: SGEN shows that it’s moving beyond the pandemic. Which means maybe it’s time for a second look.  

Specifically, the acquisition of Seagen will allow Pfizer to bolster its oncology drug portfolio. Cancer treatments continue to be one the largest drivers of growth in medicine. And Seagen already has commercially available treatments that Pfizer believes will contribute $10 billion in revenues in 2030.  

That would help the company’s bottom line, which is expected, without Seagen, to drop by single digits in the next five years. Still, PFE stock is valued inexpensively at just 7x earnings. And its dividend is extremely attractive with a yield of 4.03% and an annual payout of $1.64 per share.  

An Under-the-Radar Option for Onshoring 

The supply chain issues brought on by the Covid-19 pandemic are illustrating to American companies the importance of shortening their supply chains. This is likely to mean an “onshoring” of several key components. Corning, Inc. NYSE: GLW is a materials science company that makes glass for many applications, including flat-panel televisions and smartphones. Simply put, it has many drivers of revenue.

And a profit margin of over 9% which is higher than the sector average, ensures that earnings are solid. One concern is that the company may lose business as countries like China and India reopen after pandemic lockdowns. But American companies are becoming more sensitive to the length of their supply chains. This could work to Corning’s advantage.  

The stock is a bit expensive with a forward P/E ratio of 16x, but earnings are expected to grow by 14% over the next five years. Corning has increased its dividend in each of the last 13 years and has a current yield of 3.33% with an annual payout of $1.12 per share.  

Should you invest $1,000 in Brookfield Asset Management right now?

Before you consider Brookfield Asset Management, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Brookfield Asset Management wasn't on the list.

While Brookfield Asset Management currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

20 Stocks to Sell Now

MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by entering your email address below.

Get This Free Report
20 Stocks to Sell Now Cover

Companies Mentioned in This Article

CompanyMarketRank™Current PricePrice ChangeDividend YieldP/E RatioConsensus RatingConsensus Price Target
Brookfield Asset Management (BAM)
2.5557 of 5 stars
$32.17+1.5%3.98%N/AModerate Buy$43.57
Pfizer (PFE)
3.1034 of 5 stars
$38.37-0.7%4.27%7.55Hold$47.33
Seagen (SGEN)
1.9944 of 5 stars
$195.47+0.1%N/A-56.01Hold$190.47
Corning (GLW)
2.9853 of 5 stars
$31.28+0.7%3.58%29.51Moderate Buy$37.89
Compare These Stocks  Add These Stocks to My Watchlist 

Chris Markoch

About Chris Markoch

Contributing Author: Retirement, Individual Investing

Chris Markoch is a freelance financial copywriter with over five years of experience covering various aspects of the financial markets. You may find his writing a little different than other stock articles you’ve read. And that’s OK with him. Chris doesn’t have a traditional finance background. What he does bring to the table is a strong business and marketing background having worked for agencies that serviced Fortune 500 companies. With that in mind, he isn’t overly impressed with what companies say, and more focused on what they do. And because buyer behavior dictates so much of what happens with a stock, Chris always keeps the end consumer close in mind. Chris has been writing for MarketBeat since 2018.

Contact Chris Markoch via email at CTMarkoch@msn.com.
Is Pfizer Stock a Buy or Sell After Recent Dip? PFE Stock Analysis

Is Pfizer Stock a Buy or Sell After Recent Dip? PFE Stock Analysis

The conversation covers Pfizer's past performance, the recent acquisition of Seagen, and its potential growth in the oncology field.

Featured Articles and Offers

Search Headlines:

My Account -